이미프라민

이미프라민 · IM · Prazepine · Melipramin · DPID · Irmin · Iramil · Imizin

식별자 및 물리적 특성

CAS No.	50-49-7
분자식	C19H24N2
평균 분자량	280.4 g/mol
단동위원소 질량	280.19394877 g/mol
SMILES	CN(C)CCCN1c2ccccc2CCc2ccccc21
InChIKey	BCGWQEUPMDMJNV-UHFFFAOYSA-N
PubChem CID	3696
ChEMBL	CHEMBL11
ChEBI	CHEBI:47499
EC No.	200-042-1
DTXSID	DTXSID1043881
현지명	이미프라민

화학 및 물리적 성질

XLogP	4.8
극성 표면적	6.5
수소 결합 공여자 수	0
수소 결합 수용자 수	2
회전 가능 결합 수	4
무거운 원자 수	21
형식 전하	0
복잡도	291
의약품	DEA NFLIS-Drug Category -> AntidepressantsPharmaceuticalsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Tricyclic Antidepressants (TCAs)
LogP(분배 계수)	log Kow = 4.804.68
냄새	Odorless /hydrochloride/
Color/Form	White to off-white /hydrochloride/
용해도	CRYSTALS FROM ACETONEFREELY SOL IN WATER, LESS SOL IN ALCOHOL, SPARINGLY SOL IN ACETONE /HYDROCHLORIDE/In water, 18.2 mg/l @ 24 °C.18.2 mg/L at 24 °C
Human Drugs	Antidepressants -> Tricyclic antidepressants (TCA)Breast FeedingLactationMilk, HumanAntidepressive AgentsAntidepressive Agents, TricyclicPharmaceuticals
끓는 점	160 °C @ 0.1 MM HGbp0.1 160°
Decomposition	When heated to decomposition it emits toxic fumes of nitroxides.
녹는점	174-175174.5 °C174°C
Physical Description	Solid
Stability/Shelf Life	Imipramine hydrochloride turns yellowish or reddish on exposure to lightslight discoloration does not affect potency, but marked discoloration is associated with loss of potency. Solutions of imipramine hydrochloride are stable at pH 4-5. During storage, minute crystals may form in the injectionthe efficacy of the preparation is unaltered if the crystals are redissolved by immersing the ampul in hot water for 1 minute. /Imipramine hydrochloride/
Dissociation Constants	9.519.45
밀도	0.9935 (rough estimate)
굴절률	1.5640 (estimate)
저장 조건	Storage temp. 2-8°C
물리적 상태	Liquid
pKa(산도 계수)	pKa 9.66(H2O,t = 25,I=0.025) (Uncertain)
색상	Colorless to light yellow
용해도	18.23mg/L(24℃)
Specific Activity	60-90 Ci/mmol
BCS Class	1
EPA	Imipramine (50-49-7)

안전 및 규제

GHS 분류	This chemical does not meet GHS hazard criteria for 75% (6 of 8) of all reports.WarningH302 (12.5%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 8 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
규제 정보	Status: Active Update: 08-03-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/20142Imipramine: Does not have an individual approval but may be used under an appropriate group standard
FDA 요건	Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).
Special Reports	A REVIEW ON MECHANISM OF ACTION.[COSTA E ET ALMOLECULAR MECHANISMS IN THE ACTION OF IMIPRAMINEEXPERIENTIA 39(8) 855 (1983)]
Hazard Classes and Categories	Acute Tox. 4 (12.5%)
처리 방법	SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Treatment	Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at anytime during this period, extended monitoring is required. (L1712)
상호 작용	A PARTICULARLY SEVERE, BUT RARE, INTERACTION HAS BEEN NOTED FOLLOWING THE CONCURRENT ADMINISTRATION OF AN MAO /MONOAMINE OXIDASE/ INHIBITOR AND A TRICYCLIC ANTIDEPRESSANT. /TRICYCLIC ANTIDEPRESSANTS/

용도

Imipramine is used in depression of various etiology accompanied by motor clumsiness and enuresis in children and Parkinson’s disease.